KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBITDA (2016 - 2025)

Historic EBITDA for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $163.1 million.

  • BeOne Medicines' EBITDA rose 23562.88% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 12093.54%. This contributed to the annual value of -$568.2 million for FY2024, which is 5295.34% up from last year.
  • Latest data reveals that BeOne Medicines reported EBITDA of $163.1 million as of Q3 2025, which was up 23562.88% from $87.9 million recorded in Q2 2025.
  • BeOne Medicines' EBITDA's 5-year high stood at $190.6 million during Q4 2021, with a 5-year trough of -$474.8 million in Q2 2021.
  • Moreover, its 5-year median value for EBITDA was -$261.3 million (2024), whereas its average is -$209.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 73175.99% in 2022, then soared by 23562.88% in 2025.
  • BeOne Medicines' EBITDA (Quarter) stood at $190.6 million in 2021, then plummeted by 345.92% to -$468.6 million in 2022, then grew by 18.1% to -$383.8 million in 2023, then soared by 79.31% to -$79.4 million in 2024, then skyrocketed by 305.37% to $163.1 million in 2025.
  • Its EBITDA was $163.1 million in Q3 2025, compared to $87.9 million in Q2 2025 and $11.1 million in Q1 2025.